Type 1 Diabetes: Current Perspectives

  • Aizhan Kozhakhmetova
  • Kathleen M. GillespieEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1433)


Type 1 diabetes, resulting from the autoimmune destruction of insulin producing islet beta cells is caused by genetic and environmental determinants. Recent studies agree that counterintuitively, the major genetic susceptibility factors are decreasing in frequency as the incidence of the condition increases. This suggests a growing role for environmental determinants but these have been difficult to identify and our understanding of gene/environment effects are limited. Individuals “at risk” can be identified accurately through the presence of multiple islet autoantibodies and current efforts in type 1 diabetes research focus on improved biomarkers and strategies to prevent or reverse the condition through immunotherapy.


Type 1 diabetes Autoimmunity Insulin Islet autoantibodies Genes 


  1. 1.
    Tisch R, Devitt H (1996) Insulin-dependent diabetes mellitus. Cell 85:291–297CrossRefPubMedGoogle Scholar
  2. 2.
    Butler AE, Galasso R, Meier JJ, Basu R, Rizza RA, Butler PC (2007) Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia 50:2323–2331CrossRefPubMedGoogle Scholar
  3. 3.
    Gillespie K. (2011) The genetics of type 1 diabetes, type 1 diabetes - pathogenesis, genetics and immunotherapy, Prof. David Wagner (Ed.), ISBN: 978-953-307-362-0, Rijeka, Croatia: InTech, Available from:
  4. 4.
    Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J (2000) Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23:1516–1526CrossRefPubMedGoogle Scholar
  5. 5.
    Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of type 1 diabetes - the analysis of the data on published incidence trends. Diabetologia 42:1395–1403CrossRefPubMedGoogle Scholar
  6. 6.
    Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373:2027–2033CrossRefPubMedGoogle Scholar
  7. 7.
    Redondo MJ, Yu L, Hawa M, Mackenzie T, Pyke DA, Eisenbarth GS et al (2001) Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 44:354–362CrossRefPubMedGoogle Scholar
  8. 8.
    Schenker M, Hummel M, Ferber K, Walter M, Keller E, Albert ED et al (1999) Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: the German BABYDIAB study. Diabetologia 42:671–677CrossRefPubMedGoogle Scholar
  9. 9.
    Gillespie KM, Gale EA, Bingley PJ (2002) High familial risk and genetic susceptibility in early onset childhood diabetes. Diabetes 51:210–214CrossRefPubMedGoogle Scholar
  10. 10.
    Gillespie KM, Aitken RJ, Wilson I, Williams AJ, Bingley PJ (2014) Early onset of diabetes in the proband is the major determinant of risk in HLA DR3-DQ2/DR4-DQ8 siblings. Diabetes 63:1041–1047CrossRefPubMedGoogle Scholar
  11. 11.
    Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE et al (2007) Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450:887–892CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV et al (2013) HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients. Diabetes 62:1345–1350CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mellanby RJ, Phillips JM, Parish NM, Cooke A (2008) Both central and peripheral tolerance mechanisms play roles in diabetes prevention in NOD-E transgenic mice. Autoimmunity 41:383–394CrossRefPubMedGoogle Scholar
  14. 14.
    Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EAM et al (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89:4037–4043CrossRefPubMedGoogle Scholar
  15. 15.
    Todd JA (2010) Etiology of type 1 diabetes. Immunity 32:457–467CrossRefPubMedGoogle Scholar
  16. 16.
    Marroqui L, Santin I, Dos Santos RS, Marselli L, Marchetti P, Eizirik DL (2014) BACH2, a candidate risk gene for type 1 diabetes, regulates apoptosis in pancreatic beta-cells via JNK1 modulation and crosstalk with the candidate gene PTPN2. Diabetes 63:2516–2527CrossRefPubMedGoogle Scholar
  17. 17.
    Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, Gale EA (2004) The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 364:1699–1700CrossRefPubMedGoogle Scholar
  18. 18.
    Fourlanos S, Varney MD, Tait BD, Morahan G, Honeyman MC, Colman PG et al (2008) The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 31:1546–1549CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Knip M, Simell O (2012) Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med 2:a007690CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hermann R, Turpeinen H, Laine AP, Veijola R, Knip M, Simell O et al (2003) HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 62:162–169CrossRefPubMedGoogle Scholar
  21. 21.
    Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM et al (2004) Prediction of Autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89:3896–3902CrossRefPubMedGoogle Scholar
  23. 23.
    Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701–1710CrossRefPubMedGoogle Scholar
  24. 24.
    Bottazzo GF, Dean BM, McNally JM, Mackay EH, Swift PGF, Gamble DR (1985) In situ characterisation of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313:353–360CrossRefPubMedGoogle Scholar
  25. 25.
    Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK et al (1983) Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222:1337–1339CrossRefPubMedGoogle Scholar
  26. 26.
    Baekkeskov S, Bruining GJ, Molenaar L, Sigurdsson E, Christgau S (1989) Predictive value of Mr 64,000 antibodies for Type 1 (insulin-dependent) diabetes in a childhood population. Diabetologia 32:463AGoogle Scholar
  27. 27.
    Christie MR, Genovese S, Cassidy D, Bosi E, Brown TJ, Lai M et al (1994) Antibodies to islet 37k antigen but not to glutamate decarboxylase discriminate rapid progression to insulin-dependent diabetes mellitus in endocrine autoimmunity. Diabetologia 43:1254–1259Google Scholar
  28. 28.
    Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104:17040–17045CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S et al (2008) A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 57:2693–2697CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Edghill EL, Dix RJ, Flanagan SE, Bingley PJ, Hattersley AT, Ellard S et al (2006) HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 55:1895–1898CrossRefPubMedGoogle Scholar
  31. 31.
    Roll U, Christie MR, Fuchtensbusch M, Payton MA, Hawkes CJ, Ziegler AG (1996) Perinatal autoimmunity in offspring of diabetic parents: the German Multicenter BABY-DIAB Study: detection of humoral immune responses to islet autoantigens in early childhood. Diabetes 145:967–973CrossRefGoogle Scholar
  32. 32.
    Parikka V, Nanto-Salonen K, Saarinen M, Simell T, Ilonen J, Hyoty H et al (2012) Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 55:1926–1936CrossRefPubMedGoogle Scholar
  33. 33.
    Bingley PJ, Williams AJ (2004) Validation of autoantibody assays in type 1 diabetes: workshop programme. Autoimmunity 37:257–260CrossRefPubMedGoogle Scholar
  34. 34.
    Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA (1997) A novel micro-assay for insulin autoantibodies. J Autoimmun 10:473–478CrossRefPubMedGoogle Scholar
  35. 35.
    Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK (2013) Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 36:2266–2270CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V et al (2011) Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A 108:19018–19023CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD et al (2015) Beta Cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 125:1163–1173CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Gepts W, DeMey J (1978) Islet cell survival determined by morphology: an immunocytochemical study of the islet of Langerhans in juvenile diabetes mellitus. Diabetes 27:251–261CrossRefPubMedGoogle Scholar
  39. 39.
    Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS (1986) The histopathology of the pancreas in Type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29:267–274CrossRefPubMedGoogle Scholar
  40. 40.
    Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG (2009) Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155:173–181CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ et al (2014) The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 57:187–191CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT (2009) Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 55:2035–2039CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Diabetes and Metabolism Unit, School of Clinical Sciences, Southmead HospitalUniversity of BristolBristolUK

Personalised recommendations